OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Pharmacological Sciences is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Subscription and Copyright Information	656
Shearing of surface mucin saps tumor cell strength	550
Subscription and Copyright Information	266
Advisory Board and Contents	236
Subscription and Copyright Information	224
Subscription and Copyright Information	216
Subscription and Copyright Information	195
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	193
Structural asymmetry in FGF23 signaling	182
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	174
Cancer pathogenesis and phase targeting through condensate fragility	165
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	150
Compstatins: the dawn of clinical C3-targeted complement inhibition	143
Muscarinic receptors: from clinic to bench to clinic	138
Targeting complement in neurodegeneration: challenges, risks, and strategies	134
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	131
Therapeutic inhibition of ferroptosis in neurodegenerative disease	122
Structural pharmacology and mechanisms of GLP-1R signaling	109
Swinging the SWI/SNF complexes for cancer therapy	108
Direct in vivo CAR T cell engineering	104
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	103
Nemolizumab (Nemluvio®) for prurigo nodularis	103
Advisory Board and Contents	102
Engineering ACE2 decoy receptors to combat viral escapability	101
Leveraging human microbiomes for disease prediction and treatment	99

The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics	99
Optogenetic engineering for precision cancer immunotherapy	94
Programmable CAR immunotherapies for neurodegenerative proteinopathies	94
Phenotypic approaches for CNS drugs	91
Advisory Board and Contents	87
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	86
Advisory Board and Contents	85
A perspective on psychedelic teratogenicity: the utility of zebrafish models	84
A deep dive into degrader-induced protein-protein interfaces	84
HSV-1 as a gene delivery platform for cancer gene therapy	83
A smart hospital-driven approach to precision pharmacovigilance	79
Ribosome-directed cancer therapies: the tip of the iceberg?	72
siRNA drug Leqvio (inclisiran) to lower cholesterol	70
Genetically engineered loaded extracellular vesicles for drug delivery	68
Close to a year in TIPS’ saddle – I am optimistic	67
Thriving as members of under-represented groups in pharmacology-related careers	64
Deubiquitinating enzymes as therapeutic targets in diabetic nephropathy	64
Subscription and Copyright Information	64
Subscription and Copyright Information	64
Molecular glues evolve from serendipity to rational design	62
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	59
Mentoring future science leaders to thrive	57
Emerging approaches to induce immune tolerance to therapeutic proteins	56
Subscription and Copyright Information	55
Now you serine, now you don't	55
Bimetallic nanoadjuvants for cancer vaccines	54
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	54
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	53